Chemomab Therapeutics | POS AM:修改注册声明表
Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Adi Mor(4.8%),Kobi George(4.8%)
Chemomab Therapeutics | SC 13G:超过5%持股股东披露文件-Erik Otto(6.1%)
Chemomab Therapeutics | 6-K:外国发行人报告
Chemomab Therapeutics | 424B5:募资说明书
Chemomab Therapeutics | 6-K:外国发行人报告(业绩相关)
Chemomab Therapeutics | 6-K:外国发行人报告(业绩相关)
Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(9.99%),OrbiMed Israel GP Ltd.(9.99%)等
Chemomab Therapeutics | 144:拟议出售证券
Chemomab Therapeutics | 424B3:募资说明书
Chemomab Therapeutics | EFFECT:其他
Chemomab Therapeutics | CORRESP:信函
Chemomab Therapeutics | UPLOAD:其他
Chemomab Therapeutics | F-3:交易注册声明
Chemomab Therapeutics | 6-K:外国发行人报告(业绩相关)
Chemomab Therapeutics | SC 13G:超过5%持股股东披露文件-Sphera Funds Management Ltd.(6.56%),Sphera Global Healthcare GP Ltd.(6.56%)等
Chemomab Therapeutics | D:发行公告
Chemomab Therapeutics | 6-K:外国发行人报告(业绩相关)
Chemomab Therapeutics | 6-K:外国发行人报告
Chemomab Therapeutics | 6-K:外国发行人报告(业绩相关)
暂无数据
暂无数据